Elena Belousova
Child neurologist and epilepsy specialist in Moscow who heads a department of psychoneurology and epileptology and has been a principal investigator in international drug trials for tuberous sclerosis complex
Head, Department of Psychoneurology and Epileptology, Moscow Research Institute of Pediatrics and Pediatric Surgery (since 2003; at the institute since 1985) · Professor (2007) · Doctor of Medical Sciences (2004) · residency in child neurology, Leningrad · MD, Leningrad Pediatric Medical Institute (1980)
Portrait: Neuro-Med clinic (nevromed.ru)
Tuberous sclerosis complex (TSC) is a genetic disease in which a faulty TSC1 or TSC2 gene leaves mTOR permanently switched on. Children and adults with TSC grow benign tumours in many organs, including the brain and the kidneys, and most have epilepsy. Elena Belousova is a co-author of both large phase 3 trials of everolimus, a drug that blocks mTORC1, in this disease. In EXIST-1 (FRA2013), 117 patients with brain tumours called subependymal giant cell astrocytomas took everolimus or placebo; the tumours shrank by at least half in 35 percent of patients on the drug and in none on placebo. In EXIST-2 (BIS2013), 118 patients with kidney tumours called angiomyolipomas took part; 42 percent on everolimus had a response, against none on placebo.
These were randomised, placebo-controlled trials in people, and they are among the clearest evidence that blocking mTOR works when a genetic fault is the cause of mTOR overactivity. That does not mean the same benefit applies to people without such a mutation.
Belousova trained in medicine at the Leningrad Pediatric Medical Institute, graduating in 1980, and completed a residency in child neurology in Leningrad. She has worked since 1985 at the Moscow Research Institute of Pediatrics and Pediatric Surgery and has headed its Department of Psychoneurology and Epileptology since 2003. Her doctoral thesis (2004) was on seizures and epilepsy in children with cerebral palsy, and she became a professor in 2007. Her work covers the diagnosis and treatment of childhood epilepsy, and she has been a principal investigator in international trials in tuberous sclerosis and in Duchenne muscular dystrophy. She was named Honored Physician of the Russian Federation in 2011.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2013 | H | Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial BIS2013 Co-author of EXIST-2, the phase 3 trial in which everolimus shrank TSC-related kidney angiomyolipomas in 42 percent of patients versus none on placebo. |
| 2013 | H | Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial FRA2013 Co-author of EXIST-1, the phase 3 trial in which everolimus shrank TSC-related brain tumours in 35 percent of patients versus none on placebo. |
Co-authors in the Atlas 8
People with a profile here who share at least one study with Elena Belousova.
ShowHide
- David Lebwohl 2 shared studies Medical oncologist and drug developer who led the clinical development of everolimus (Afinitor) at Novartis through approvals in several cancers and tuberous sclerosis, and later served as Chief Medical Officer of the gene-editing company Intellia Therapeutics
- Michael D. Frost 2 shared studies Co-investigator on the EXIST-1 and EXIST-2 trials showing that the mTOR inhibitor everolimus shrinks tuberous sclerosis tumours in the brain and kidney
- Tarek Sahmoud 2 shared studies Physician and epidemiologist who worked as a clinical program head in Novartis oncology drug development during the everolimus trials, and later as chief medical officer at several cancer drug companies
- David N. Franz Led the EXIST-1 trial showing that the mTOR inhibitor everolimus shrinks the brain tumours (SEGAs) of tuberous sclerosis, and helped run the first sirolimus trial for its kidney tumours
- John J. Bissler Led the first clinical trial showing that the mTOR inhibitor sirolimus shrinks kidney angiomyolipomas in tuberous sclerosis, and the EXIST-2 trial of everolimus for the same tumours
- Klemens Budde Kidney and transplant physician who took part as an investigator in the EXIST-2 trial of everolimus for kidney tumours in tuberous sclerosis and LAM; clinician-investigator rather than a bench mTOR researcher.
- Sergiusz Jóźwiak A child neurologist known for work on tuberous sclerosis complex and a senior author of the EXIST-1 trial of everolimus.
- Vicky H Whittemore Neuroscientist and NIH program director for epilepsy and ME/CFS research who spent over two decades working for patient organisations, including the Tuberous Sclerosis Alliance
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.